(Q38415842)

2 September 2017

title

Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection (English)

1 reference

2 September 2017

0 references

0 references

1 reference

ChEBI release 2020-05-28

26

Anthony S Fauci

1 reference

2 September 2017

Amy Nelson

4

0 references

David E. Kleiner

object named as

David E Kleiner

20

0 references

Shyam Kottilil

28

object named as

Shyam Kottilil

1 reference

2 September 2017

11

Mohammad Sajadi

1 reference

2 September 2017

16

Gebeyehu Teferi

1 reference

2 September 2017

12

Sreetha Sidharthan

1 reference

2 September 2017

9

Chloe Gross

1 reference

2 September 2017

18

Michael Proschan

1 reference

2 September 2017

13

Zayani Sims

1 reference

2 September 2017

23

Phillip S Pang

1 reference

2 September 2017

7

Dimitra Bon

1 reference

2 September 2017

8

Rachel Silk

1 reference

2 September 2017

27

Henry Masur

1 reference

2 September 2017

17

Rohit Talwani

1 reference

2 September 2017

1

Anu Osinusi

1 reference

2 September 2017

Kerry Townsend

2

1 reference

2 September 2017

Anita Kohli

3

1 reference

2 September 2017

Cassie Seamon

5

1 reference

2 September 2017

Eric G Meissner

6

1 reference

2 September 2017

Angie Price

10

1 reference

2 September 2017

Eva Herrmann

14

1 reference

2 September 2017

John Hogan

15

1 reference

2 September 2017

Veronica Jenkins

19

1 reference

2 September 2017

Brad J Wood

21

1 reference

2 September 2017

G Mani Subramanian

22

1 reference

2 September 2017

John G McHutchison

24

1 reference

2 September 2017

Michael A Polis

25

1 reference

2 September 2017

language of work or name

English

0 references

publication date

1 March 2015

1 reference

The Journal of the American Medical Association

2 September 2017

published in

1 reference

2 September 2017

volume

313

1 reference

2 September 2017

issue

12

1 reference

2 September 2017

page(s)

1232-1239

1 reference

Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis

2 September 2017

cites work

1 reference

12 December 2020

Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients

1 reference

12 December 2020

Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons

1 reference

12 December 2020

Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial

1 reference

12 December 2020

1 reference

12 December 2020

A new equation to estimate glomerular filtration rate

1 reference

12 December 2020

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

1 reference

12 December 2020

A perspective on modelling hepatitis C virus infection

1 reference

12 December 2020

Understanding hepatitis C viral dynamics with direct-acting antiviral agents due to the interplay between intracellular replication and cellular infection dynamics

1 reference

12 December 2020

Use of illumina deep sequencing technology to differentiate hepatitis C virus variants

1 reference

12 December 2020

Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV/HCV

1 reference

12 December 2020

Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence

1 reference

12 December 2020

A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus

1 reference

12 December 2020

Current management of hepatitis C virus infection in patients with HIV co-infection

1 reference

12 December 2020

Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial

1 reference

12 December 2020

Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial

1 reference

12 December 2020

Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial.

1 reference

12 December 2020

Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial

1 reference

12 December 2020

Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis

1 reference

12 December 2020

Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection

1 reference

12 December 2020

Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection

1 reference

12 December 2020

Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection

1 reference

12 December 2020

Simeprevir (TMC435) with pegylated interferon/ribavirin in patients coinfected with HCV genotype 1 and HIV-1: a phase 3 study

1 reference

12 December 2020

Identifiers

DOI

10.1001/JAMA.2015.1373

1 reference

2 September 2017

0 references

1 reference